Brand Reference: Vibramycin, Oracea (40 mg sub-antimicrobial)
| Metric | Verified Benchmark | Source |
|---|---|---|
| Doxycycline Hyclate / Monohydrate RxNorm Concept ID | 3640 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1180 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $52.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $7.80 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $10.00 / mo | 29 Zero-PHI Verified Patient Logs |
At 40 mg modified-release dosing, acts purely as a non-antibiotic host-response inhibitor of neutrophil matrix metalloproteinase-8/9 and phospholipase A2 in papulopustular rosacea; at 100 mg BID, blocks bacterial 30S aminoacyl-tRNA binding in inflammatory acne.
Out-of-pocket price dispersion on Doxycycline Hyclate / Monohydrate spans $7.80 to $52.00 per 30-day fill: pharmacy acquisition benchmarks sit near $0.1180/unit, allowing cash buyers bypassing PBM spread pricing to retain $44.20 each month (85% reduction).
With 18–22 hours residence kinetics and 90%–100% oral (chelated by dairy Ca2+/Mg2+/Fe2+) bioavailability, Doxycycline Hyclate / Monohydrate undergoes minimal hepatic metabolism; intestinal chelation fecal elimination + 40% renal and establishes therapeutic activity over 2–4 weeks inflammatory papule resolution.
Standard adult regimens span 40 mg MR PO QAM (Oracea sub-antimicrobial rosacea), 50–100 mg PO BID x 8–12 weeks max with retinoid. Prescribers screen specifically against pregnancy & children < 8 years (dental enamel staining); esophageal stricture if taken supine without water; concurrent isotretinoin (pseudotumor cerebri risk), while community micro-logs most frequently note uv phototoxicity sunburn (26% of reports), nausea (19% of reports), pill esophagitis if taken dry (14% of reports).
Across 29 verified cash-pay logs, Doxycycline Hyclate / Monohydrate achieves a 81.50% Worth-It rating with out-of-pocket spend averaging $10.00/mo versus $52.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 40 mg MR PO QAM (Oracea sub-antimicrobial rosacea) for Doxycycline Hyclate / Monohydrate; monthly out-of-pocket dropped to $6.86 compared with $52.00 retail.
Completed 10 weeks on Doxycycline Hyclate / Monohydrate (50–100 mg PO BID x 8–12 weeks max with retinoid). Zero notable side effects on steady dosing.
Consistent biomarker response on 40 mg MR PO QAM (Oracea sub-antimicrobial rosacea) Doxycycline Hyclate / Monohydrate sourced via Local Pharmacy ($9.05/mo cash pay without insurance prior authorization).